REFERENCES
- Hollon MR Direct-to-consumer marketing of prescription drugs: Creating con-sumer demand. JAMA. 1999; 281:382–4.
- Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999; 281:380–1.
- Wilkes MS, Bell RA, Kravitz RL. Direct-to-consumer prescription drug adver-tising: Trends, impact, and implications. Health Aff 2000; 19:110–28.
- Lavidge RJ, Steiner GA. A model for predictive measurements of advertising effectiveness. J Marketing. 1961; 4:59–62.
- Glass HE, Corrigan MH. Physician participation in clinical studies and subse-quent prescribing of the new drug. AMJ. forthcoming.
- Glass HE, Kane RA. Why investigators take part in clinical trials. Appl Clin Tri-als. 2000; 9(6):46–54.
- IMS Health. Xponent® [database]. Plymouth Meeting, PA: IMS Health; 1975. Updated daily.
- Hovde M, Seskin R. Selecting U.S. clinical investigators. Appl Clin Trials. 1997; 6(2):34–42.
- Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA. 2000; 283:373–80.
- Glass HE, Sullivan JM. Managing clinical grant costs through the use of unaffil-iated investigators. Drug Info J. 1995; 29:751–9.
- Rogers EM. Diffusion of innovations. 1st ed. New York: The Free Press; 1962:261–6.